TRPV1 and cancer: Concerning to cancer pain, a phase I clinical trial is being carried out to determine the efficacy of periganglionic/intrathecal administration of the potent TRPV1 agonist resiniferatoxin in advanced cancer patients with bone pain (Clinical Trials, 2017).